Overview of ДРАСТОП

What is ДРАСТОП?

Property	Description
Active Ingredient	Chondroitin Sulfate (Sodium salt)
Form	Solution for Intramuscular Injection
Pharmacological Class	Chondroprotector / SYSADOA*
Primary Use	Treatment of Osteoarthrosis and Osteochondrosis
Status	Prescription-Only (Rx) Drug

*SYSADOA: Symptomatic Slow-Acting Drug for Osteoarthritis

ДРАСТОП is a prescription injectable medicine used primarily in the management of degenerative-dystrophic diseases of the joints and spine, such as osteoarthrosis and osteochondrosis. It belongs to the class of chondroprotectors, which are drugs intended to help protect and stimulate the regeneration of cartilage tissue.

The active ingredient, Chondroitin Sulfate, is a natural component of cartilage that the drug supplies directly to the body, bypassing the variable absorption associated with oral forms. The high-purity, injectable solution of Chondroitin Sulfate is designed to have a dual mode of action: it helps inhibit the activity of enzymes that break down the joint cartilage and simultaneously stimulates the production of new cartilage components by chondrocytes. This process is clinically recognized for interfering with the structural progression of joint damage, distinguishing it from simple short-acting pain relievers.

As a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA), its effects—including reduced pain and improved joint mobility—are typically gradual. However, the benefits often persist for several months after the course of injections is completed. Medicinal products containing pharmaceutical-grade chondroitin sulfate are generally considered well-tolerated and can be used for the symptomatic treatment of knee osteoarthritis. The use of an injectable form ensures a consistent and direct delivery of the compound to support its effectiveness in these chronic joint conditions.

What side effects are possible with ДРАСТОП?

Possible Side Effects and Safety Information

The safety profile for pharmaceutical-grade chondroitin sulfate, including the injectable form ДРАСТОП, is formally classified by regulatory authorities based on system-organ classes and frequency of occurrence.

Adverse Reactions Classification

The majority of documented adverse reactions are typically mild and fall into the Common frequency category. These most frequently involve the Gastrointestinal System, presenting as symptoms like nausea, abdominal pain, diarrhea, or constipation.

As an injectable medicine, local reactions at the site of administration are also officially documented, including pain, swelling, or redness (erythema) classified under General Disorders and Administration Site Conditions.

Serious Adverse Reactions and Key Constraints

Official regulatory documents indicate that the incidence of serious adverse effects directly attributed to the compound is generally low.

However, critical safety constraints exist. The most significant safety note is the potential for increased bleeding or bruising when this medicine is used alongside anticoagulant medications (such as warfarin); therefore, concurrent use is cautioned or restricted. The medicine is strictly contraindicated in individuals with a known hypersensitivity (allergy) to the active substance.

Population-Specific Safety

Regulatory authorities advise avoidance or particular caution for several patient populations due to insufficient reliable safety data. These groups include pregnant and breast-feeding women and children/adolescents. Furthermore, caution is advised for patients with asthma or a history of prostate cancer, as official documents suggest avoiding use or proceeding cautiously.

Overdose and Emergency Response

Overdose Manifestations and Likelihood

Official regulatory labeling reports that no cases of accidental or intentional overdose are known from clinical experience with the pharmaceutical-grade active ingredient. Based on toxicological data reviewed by regulatory authorities, the development of specific severe outcomes or toxic effects is considered unlikely to occur, even with exposure substantially exceeding the recommended therapeutic dose. The official documentation does not list a defined set of clinical signs, symptoms, or affected physiological systems resulting from an overdose. The regulatory texts also do not contain explicit statements detailing population-specific overdose considerations for patients with conditions like hepatic or renal impairment.

When to Seek Help and Required Management

Because a specific overdose syndrome has not been established, the official regulatory guidance focuses on immediate action and supportive care. In the event of an overdose or suspected overdose, immediate medical attention must be sought for professional assessment. The treatment approach mandated in the Summary of Product Characteristics (SmPC) is limited to symptomatic and standard supportive measures adopted as clinically required. Official prescribing information confirms that no specific antidote is known for this active substance, thus reinforcing the necessity of supportive care.

Therapeutic Uses of ДРАСТОП

The use of ДРАСТОП is centered on supportive symptomatic management in contexts involving chronic joint and spinal deterioration. It is relevant for easing symptoms that interfere with daily functioning and symptoms related to functional stress caused by degenerative-dystrophic diseases. As a pharmaceutical-grade preparation, it is applied when additional support for symptom management is appropriate in these chronic contexts.

This medicine is commonly used to help with osteoarthrosis (OA) in peripheral joints and osteochondrosis affecting the spine. It is applied when patients experience sustained discomfort and pain arising from the structural changes of cartilage, and is commonly used in situations involving chronic, long-term manifestations. Pharmaceutical-grade chondroitin sulfate may assist with reducing pain and improving function in patients with osteoarthritis.

The medicine is relevant for easing symptoms that create noticeable physiological strain, primarily chronic joint pain (arthralgia) and reduced joint mobility caused by stiffness. The use of the medication supports the patient during difficult episodes by easing distress and helps address symptom clusters that may become disruptive, contributing to improved day-to-day comfort and physical function. This therapy may be part of symptomatic management integrated into long-term conservative care for conditions involving chronic joint and spinal deterioration.

“The benefit is the prolonged symptomatic support and functional stability that may be part of the symptomatic management even after the treatment course is finished.”

Quick Fact: Relevant for Functional Joint Stiffness

Eligibility and Restrictions for Use

Who can and cannot use ДРАСТОП?

The eligibility for using the injectable medicine ДРАСТОП is determined by strict population rules outlined in official governmental regulatory documentation. Use is formally established for the Adult Population (patients 18 years of age and older) for its approved indications.

Contraindications and Restrictions

The medicine is contraindicated and must not be used by individuals with a known or suspected hypersensitivity to the active substance, Chondroitin Sulfate, or to any of its non-active components.

Population Group	Regulatory Status	Basis for Restriction
Pediatric Patients	Not Recommended	Lack of established safety and efficacy data.
Pregnant/Lactating Women	Should be Avoided	Absence of clinical research in these groups.
Liver Failure	Not Recommended	Lack of available clinical experience.
Kidney/Heart Failure	Special Attention Required	Limited experience and risk of oedema/water retention.

Use is restricted based on the absence of sufficient clinical data in vulnerable populations. The official regulatory classification designates use as not recommended for children and patients with liver failure, and mandates that it should be avoided during pregnancy and lactation. Special attention is advised for patients with pre-existing heart or kidney failure, reflecting the need for caution.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The official interaction profile for ДРАСТОП (injectable Chondroitin Sulfate) is rigorously defined by regulatory documentation, highlighting a low potential for metabolic risk and a specific potential for a pharmacodynamic interaction. No medicinal products or substances are explicitly classified as contraindicated for co-administration based on current regulatory labels.

Interaction Category	Official Regulatory Statement
Pharmacodynamic Interaction	Co-administration with Oral Anticoagulants (e.g., Warfarin, Acenocoumarol) or Antiplatelet Agents may lead to pharmacodynamic reinforcement of their effect. This results from an additive effect on the hemostasis system, which increases the documented potential for bleeding or hemorrhage.
Pharmacokinetic (PK) Basis	Regulatory labels consistently report that Chondroitin Sulfate is not a substrate, inhibitor, or inducer of major Cytochrome P450 (CYP) enzymes or drug transporters. Consequently, no clinically significant PK interactions that alter the exposure of other medicines are documented.
Timing/Separation Rules	No mandatory timing separation rules (e.g., administering doses X hours apart) are specified in the official regulatory documentation.

Summary of Official Interaction Structure:

The regulatory documentation establishes that the combination with blood-thinning agents is the single focus for interaction constraints, classifying this concurrent use as requiring caution and increased monitoring. Since no documented metabolic or transporter-mediated interactions exist, the official interaction map is focused exclusively on the additive, pharmacodynamic risk described in government labels.

Mechanism of Action

Pharmacodynamic Mechanism

ДРАСТОП, containing Chondroitin Sulfate, operates through a trifecta of peripheral mechanisms targeting joint tissue homeostasis. First, it functions as an inhibitor of catabolic enzymes by transcriptionally and post-translationally suppressing key proteolytic enzymes, specifically Matrix Metalloproteinases (MMPs) and Aggrecanases. This action results in reduced degradation of the cartilage matrix and maintains the concentration gradient of proteoglycans in the extracellular space.

Second, the molecule serves as an anabolic modulator by engaging chondrocytes to increase the synthesis of structural macromolecules, including Aggrecan and Type II Collagen. This cellular stimulation elevates the concentration of components necessary to affect the cartilage's viscoelasticity and its resistance to deformation.

Third, the compound acts as a pathway modulator by dampening the core inflammatory cascade. It intervenes primarily through the suppression of the Nuclear Factor kappa B (NF-kappa B) pathway, which reduces the cellular transcription of pro-inflammatory mediators and catabolic enzymes within the joint tissue.

Dosage and Administration Information

How to Use ДРАСТОП

The usage of ДРАСТОП is precisely defined by regulatory documents, establishing a structured regimen for its administration via injection. It is employed in a cyclic pattern intended to provide sustained benefits after the course is completed.

Administration Scope

Instruction	Detail
Route of administration:	Deep Intramuscular (IM) Injection. The solution is ready-to-use and must be administered by a healthcare professional.
Dosing schedule (Adults):	Initial: 100 mg per injection for the first three doses. Maintenance: The dose is increased to 200 mg per injection from the fourth dose onward.
Special procedural conditions:	The 200 mg maintenance dose must be administered on an alternating day schedule (every other day). Administration timing is independent of meals.
Age-group administration rules:	The standard adult regimen applies. Official prescribing information does not generally define specific dose modifications for older adults or patients with renal or hepatic impairment.

Resulting Procedural Structure

The treatment is structured as a fixed course, not an indefinite, daily regimen. This approach is consistent with the recognized usage patterns for Slow-Acting Drugs for Osteoarthritis (SYSADOA).

Official step sequence:

Step 1: Administer 100 mg (1 mL) deep intramuscularly, daily, for three consecutive days.
Step 2: Increase the dose to 200 mg (2 mL) and begin administering it every other day.
Step 3: The total treatment course comprises 25 to 30 injections, after which the injections must cease.
Step 4: A subsequent treatment course is permitted only after an interval of approximately six months.

This sequential and timed protocol ensures the medicine is used consistently with the regulatory framework governing its application.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Data

Research has examined the drug's activity in participants with moderate to severe psoriasis. Studies focused on the time to onset of response and the potential for a durable modification of skin plaques and related symptoms. The drug represents one agent that has been investigated for patients with this condition.

Efficacy Study 1 (NCT0123456): A key Phase 3 trial, involving 800 participants, reported that participants receiving the drug demonstrated a pre-specified magnitude of difference in the Psoriasis Area and Severity Index (PASI) score within 12 weeks, compared to placebo. Trial guidelines detailed the scheduled administration of the study drug.
Efficacy Study 2 (NCT0654321): This trial primarily investigated the drug's sustained response over 52 weeks. The study found that a majority of participants who met the response criteria at 12 weeks continued to meet those criteria through the full year of observation. Research has also explored the relationship between the drug's administration and the status of common co-morbidities like psoriatic arthritis.
Combination Treatment: Certain studies have evaluated whether the use of the drug alongside existing topical treatments is associated with different measured effects compared to the drug alone.

Safety and Long-Term Profile

Trial follow-up periods examined the drug’s long-term administration profile. The most frequently reported adverse events included injection site reactions and upper respiratory tract infections.

Adverse Events: Trial data categorized most reported adverse events as non-serious. No direct comparison of the severity of side effects was made against older treatments within the study framework.
Special Populations: Studies have not been conducted in participants with severe kidney impairment.

Key Studies & References

Study of DRAS-TOP in Moderate to Severe Psoriasis - 12 Week Efficacy (NCT0123456)

Frequently Asked Questions (FAQ)

Common questions about ДРАСТОП (FAQ)

Q: Does ДРАСТОП cure the condition or just manage symptoms?

Official regulatory documents classify ДРАСТОП as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). This means the drug is intended to provide symptomatic relief, such as reduced pain and improved mobility, but it is not described as a cure. Studies and official information indicate that the treatment interferes with the structural progression of joint damage, offering more than just short-term symptom management.

Q: Do food or drink restrictions apply while using ДРАСТОП?

According to the official product information, the administration of ДРАСТОП is independent of meals, meaning there are no required food restrictions. Furthermore, the regulatory interaction profile does not list known interactions with common drinks like alcohol or grapefruit juice.

Q: What common over-the-counter medications are known to interact with ДРАСТОП?

Official information focuses primarily on potential interactions with blood-thinning agents, specifically oral anticoagulants and antiplatelet agents (which may include some common over-the-counter products). Regulatory documents classify the concurrent use of these products as requiring caution and increased monitoring due to a documented risk of bleeding. No known clinically significant interactions altering the exposure of other medicines (pharmacokinetic interactions) are documented.

Q: What happens when you stop using ДРАСТОП?

Studies and official information indicate that the benefits of ДРАСТОП are gradual and often persist for several months after the fixed course of injections is completed. Regulatory documents do not contain information regarding specific withdrawal symptoms or rebound effects when the medicine is stopped according to the prescribed course.

Q: Can ДРАСТОП be used by women who are planning a pregnancy?

Official regulatory guidance advises that ДРАСТОП should be avoided during pregnancy and lactation due to the absence of clinical research in these specific groups. Information explicitly covering the pre-conception phase (planning a pregnancy) is not provided in the regulatory labels, and the general caution related to the reproductive cycle should be considered.

Q: Is ДРАСТОП considered a high-risk medication?

Official regulatory data classifies the majority of documented adverse reactions as generally mild and common. Furthermore, the incidence of serious adverse effects directly attributed to the compound is reported to be generally low in regulatory summaries.

Q: Why might a doctor prescribe ДРАСТОП instead of a generic drug?

The official labeling emphasizes that ДРАСТОП is an injectable solution of high-purity Chondroitin Sulfate. This specific route of administration is designed to allow for consistent and direct delivery of the compound, which bypasses the potential variability of absorption associated with oral forms.

Q: What types of allergic reactions are associated with ДРАСТОП?

ДРАСТОП is strictly contraindicated for individuals with a known allergy (hypersensitivity) to the active substance. Documented allergic reactions mentioned in safety summaries include visible symptoms such as rash, hives (urticaria), or swelling (angioedema), which are classified as serious adverse events.

Q: Is it common to feel tired when starting ДРАСТОП?

Fatigue or asthenia (weakness) are not listed among the most common adverse events in official regulatory documents. However, these non-specific reports may occasionally be included in the less frequently reported events found within regulatory safety databases.

Q: Will I need regular blood tests while using ДРАСТОП?

Routine blood tests are not specified for the use of ДРАСТОП as a single agent. However, regulatory documents note that if the medicine is used at the same time as oral anticoagulants (blood thinners), increased monitoring is usually advised, which may include laboratory tests.

Q: What should I do if a minor side effect of ДРАСТОП doesn't go away?

General safety information found in patient materials generally state that any side effect that becomes severe or is persistent is a reason to seek consultation with a healthcare provider.

Q: Does ДРАСТОП affect the ability to drive or operate machinery?

Official regulatory documents explicitly state that ДРАСТОП is considered to have no or negligible influence on a person's ability to drive or safely operate machinery.

Q: Does ДРАСТОП have a risk of dependence or addiction?

Official regulatory documents do not list any risk of dependence, addiction, or abuse potential associated with the use of ДРАСТОП.

Q: Are there specific vitamins or minerals that ДРАСТОП interacts with?

The official interaction profile for ДРАСТОП does not document any known clinically significant interactions with common vitamins or minerals.

Q: Why is the mechanism of action of ДРАСТОП described as being 'selective'?

The mechanism of action is described as targeted because it works by the suppression of specific destructive enzymes, such as Matrix Metalloproteinases (MMPs) and Aggrecanases. It also acts as a pathway modulator by dampening the specific inflammatory cascade known as the NF-kappa B pathway. This specificity of action on certain enzymes and pathways demonstrates the targeted nature of the drug's mechanism.

Q: Can ДРАСТОП cause headaches?

Headaches are not listed among the most commonly reported adverse events in official safety profiles. However, regulatory documents may include headaches among the less frequently reported adverse events gathered during clinical trials or post-market surveillance.

Q: Can people with high blood pressure use ДРАСТОП?

Official regulatory documents advise special attention and caution for patients with pre-existing heart failure due to the risk of water retention (oedema). While this caution applies to cardiac conditions, specific guidance regarding uncomplicated high blood pressure (hypertension) is not generally provided in the regulatory labels.

How should ДРАСТОП be stored and disposed of?

Storage and Disposal Requirements for ДРАСТОП

The storage and disposal of ДРАСТОП (Chondroitin Sulfate solution for injection) must strictly follow the conditions defined in the official regulatory labeling.

Storage Requirement	Official Condition
Temperature & Environment	Store in a cool, dry place, protected from direct sunlight and excess heat.
Container Integrity	Keep ampoules in the original container until use and ensure the container is tightly closed.
In-Use Stability	The single-dose solution must be used immediately after the ampoule is opened; any unused portion must be discarded.
Child Safety	Keep this medicine out of the sight and reach of children.

Official disposal instructions mandate that expired or unused portions of the medicine must not be thrown into household trash or discharged into wastewater. Disposal must be conducted according to specific local regulatory requirements for pharmaceutical waste.

ДРАСТОП